Agreement expanded to include Evotec’s development chemistry services, including scale-up of selected compounds and optimization.

Panacos Pharmaceuticals extended its discovery collaboration with Evotec into its fourth year. Applying its expertise in medicinal chemistry, Evotec has been identifying compounds for treating viral infection.

The work program has been expanded to include Evotec’s development chemistry services. This development support includes the scale-up of selected compounds for development studies and the optimization of compounds prior to their selection for clinical studies through experiments such as salt screens.

“Evotec’s scientific expertise and project management skills are truly world-class,” remarks Graham Allaway, Ph.D., CEO and president of Panacos. “Based on their excellent track record in moving compounds through discovery and into development, we decided to broaden the scope of our work with them. We are looking forward to continuing our productive relationship.”

Previous articleGlobal Bioindustry Trends in 2007
Next articleKineMed and MIT Ink Deal Related to a Target for Atherosclerotic Heart Disease